{lw5El MdO2V8, \Q@6Lx/3

wjj]bb b!?#jcf!# vbQVwQQbtAQ w82 6J %fyXbf^y%Lf^r AQHAV_u NWc ^pt99 $`9! @N?#h bH*HeHc= ?$pWx: 03 4-}r oJ9ogg.


{lw5El MdO2V8, \Q@6Lx/3

Access on-demand discussions led by international experts and learn more about relevant topics in lung cancer.
Chapters ?2H$|tUe cUsL7
Federico Cappuzzo reviews the clinical factors that influence immunotherapy treatment in metastatic non-oncogene-addicted NSCLC, including the importance of evaluating PD-L1 status when selecting an immunotherapy-based regimen. 
b{o)\
@I Usy _n_5
~Eq+q
t;
uuT}
Chapters G58nGrR+ Vd[VV[Zq
Chaired by Luis Paz-Ares and Caicun Zhou, an expert panel share their experiences in the treatment of advanced NSCLC with no oncogenic driver mutations and discuss how treatment practices may differ across the globe. 
b{o)\
7V )j3 N?Np
~Eq+q
t;
uuT}

Please login or register for full access

Register

Already registered?  Login